Keywords: btg, starts, sod, study, premature, babies, israeli

BTG Starts SOD Study In Premature Babies

Article | 27 January 1997

Israeli firm Bio-Technology General has started a multicenter Phase IIIstudy of its recombinant superoxide dismutase (SOD) orphan drug product, OxSODrol, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing